ASCO Announces Top Studies to Be Presented During Virtual Cancer Science Meeting, May 29-31

New Research on the Impact of COVID-19 on Patients With Cancer, Precision Medicine, and Access to Care to be Featured in the ASCO20 Virtual Scientific Program

For immediate release
April 29, 2020

Contact
Rachel Cagan
571-483-1684
rachel.cagan@asco.org

ALEXANDRIA, Va. – This year the American Society of Clinical Oncology (ASCO) will deliver the latest cancer science to the global oncology community in a new virtual format. Advances in immunotherapies and targeted therapies for lung, colorectal, ovarian, and bladder cancers; improvements in access to cancer care, as well as the impact of COVID-19 on people with cancer are among the topics that will be highlighted in the ASCO20 Virtual Scientific Program’s official Press Program.

The ASCO20 Virtual Scientific Program, to be held May 29-31, will provide an engaging lineup of scheduled and on-demand scientific content across a variety of approaches, disciplines, and specialties. The theme of this year’s meeting is Unite and Conquer: Accelerating Progress Together.

Approximately 2,215 abstracts were accepted for presentation during the ASCO20 Virtual Scientific Program, and more than 3,400 additional abstracts were accepted for online publication. The vast majority of these abstracts will be publicly posted on abstracts.asco.org on Wednesday, May 13, at 5:00 p.m. ET. Late-Breaking Abstracts (LBAs), including Plenary abstracts, will be released online on Thursday, May 28, at 5:00 p.m. ET. The complete
embargo schedule is available online.

EMBARGOED PRESSCAST – Tuesday, May 12, 1:00-2:30 p.m. ET
An embargoed virtual presscast for credentialed media will be held on May 12 to highlight the following studies (embargo will lift on May 13 at 5:00 p.m. ET):

- The first national-scale study on cancer mortality rates in states with and without Medicaid expansion after the adoption of the Affordable Care Act. (Abstract 2003)
- A phase III trial assessing survival after maintenance treatment with the PARP inhibitor olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. (Abstract 6002)
- A randomized controlled trial examining the use of videoconference interventions to reduce anxiety and distress in caregivers who live far away from patients with cancer. (Abstract 12123)
- International study examining the survival benefit of quitting smoking, even shortly before a lung cancer diagnosis. (Abstract 1512)
- A prospective study on quality of life for older patients after integrating geriatric assessment and management into cancer care. (Abstract 12011)

EMBARGOED PRESSCAST – Tuesday, May 26, 2:00-3:30 p.m. ET
An embargoed virtual presscast for media will be held on May 26 to highlight the following studies (embargo will lift on May 28 at 5:00 p.m. ET):

- Data from the COVID-19 and Cancer Consortium (CCC19) examining mortality and severe illness among patients with cancer who have contracted COVID-19, and use of azithromycin and hydroxychloroquine. (Abstract LBA110)
- Latest global research on COVID-19 in patients with thoracic cancers examining the impact of specific cancer treatments on outcomes. (Abstract LBA111)
- Phase III Keynote-177 trial comparing pembrolizumab to standard therapy as first-line treatment for select patients with advanced colorectal cancer. (Abstract LBA4, Plenary)
- Phase III study assessing the efficacy of adjuvant use of targeted agent osimertinib in patients with localized non-small-cell lung cancer and EGFR mutation after complete tumor resection and adjuvant chemotherapy. (LBA5, Plenary)
- Phase III interim analysis examining maintenance treatment with the immunotherapy avelumab after platinum-based first-line chemotherapy in advanced bladder cancer. (Abstract LBA1, Plenary)
- Phase II study looking at avelumab in patients with gestational trophoblastic tumors resistant to chemotherapy. (Abstract LBA6008)
- INFORM study examining use of precision medicine for pediatric cancers with poor prognosis. (Abstract LBA10503)

MEDIA RESOURCES
Apply for/renew ASCO media credentials
To participate in the embargoed presscasts, access embargoed press materials, and/or view presentations from the ASCO20 Virtual Scientific Program, please visit ASCO’s Media Headquarters at mediahq.asco.org. Step-by-step instructions are available online.

**Annual Meeting Media Resource Center**: Visit asco.org/AMMRC for press releases, the virtual press briefing schedule, embargo policies, high-resolution photos, and the Virtual Press Room (an online repository of corporate and institutional press materials from third-party organizations).

**Cancer.Net**: ASCO’s website for oncologist-approved cancer information

**About ASCO:**

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. Conquer Cancer, the ASCO Foundation, supports the Society by funding groundbreaking research and education across cancer’s full continuum. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on [Facebook](http://Facebook), [Twitter](http://Twitter), [LinkedIn](http://LinkedIn), and [YouTube](http://YouTube).